Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh

The fourth Riyadh Global Medical Biotechnology Summit (RGMBS) closed on September 16 with 46 agreements signed. Disclosed announcements total 5.5 billion SAR (about $1.47 billion). Over three days, speakers including Keith Flaherty of Mass General Cancer Center, Matthew Porteus of Stanford University, Alex Shalek of MIT, and Kasim Kutay, CEO of Novo Holdings, joined Saudi regulators, investors, and researchers. On the exhibition floor, global companies like AstraZeneca, Thermo Fisher Scientific, and Vertex Pharmaceuticals sat alongside local Saudi companies.

Signatures are the easy part. Dr. Abdulrahman Alshaya, Chairman of RGMBS and Chairman of Collaboration and Partnerships at the King Abdullah International Medical Research Center (KAIMRC), says the harder work is turning each agreement into a working program.

RGMBS is organized by the Ministry of National Guard Health Affairs (MNGHA), King Abdullah International Medical Research Center (KAIMRC), and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS). It sits within Saudi Arabia’s National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotech by 2040.

Built for system enablement

Dr. Alshaya says the summit was designed around a problem trade exhibitions do not solve. Regional business-to-business shows generate short term transactions, he argues, but not the alignment of policy and capital that builds a sustainable industry. RGMBS focuses instead on system enablement, targeted at executives so that decisions made in the room carry bigger impact. “Biotechnology creates value only when discovery, regulation, manufacturing, and capital move together,” he says. That is the National Biotechnology Strategy put into practice: its 2040 target depends on those parts moving as one.

The program brought those groups together across four pillars, six tracks, and seven closed-door executive sessions. Two forums ran alongside it. The Life Sciences Innovation Forum focused on company building, with panels on commercialization and venture scaling, while early-stage companies pitched to venture investors. The Next Generation Biotechnologist Forum trained emerging scientists through expert-led sessions, workshops, and bootcamps in trending topics.

Announcements that lower the cost of entry

Several announcements targeted the friction that slows investment. BioSync, launched with the Ministry of Investment, consolidates the Kingdom’s biotech ecosystem into a single investor platform aligned with roughly 20 prioritized medical biotechnology opportunities. The Saudi Data and Artificial Intelligence Authority (SDAIA) Regulatory Sandbox gives developers a supervised setting to test AI-driven health solutions, reducing the cost of early validation. Dr. Alshaya sees both as foundational, lowering transaction costs for every partner that follows.

Ranking agreements by substance

He declines to rank the 46 agreements by headline value, noting that many were left undisclosed at the request of the parties involved. Technology transfer deals matter most, he says: partners establishing manufacturing hubs in the Kingdom for innovative products, such as GLP-1 therapies rather than generics, bring know-how, capacity, and supply chains with them. He describes technology transfer as “the asset that compounds.”

To become a program, he says, an agreement needs a named owner, a funded first project, agreed data and intellectual property governance, and a first deliverable date. “Otherwise it is a statement of intent.”

Where the science is heading

Dr. Alshaya points to precision medicine, with the emphasis shifting from lifelong treatment toward prevention and cure. The National Biotechnology Strategy concentrates on vaccines, genomics, and biomanufacturing under one operating model: co-develop, co-manufacture, co-commercialize. Saudi institutions, he says, can contribute as research partners rather than adopters, with systems such as MNGHA linking care, research, and clinical trials. His test for a genuine partnership is plain: international partners co-lead studies and share ownership, rather than simply using local samples.

Fragmentation as the main barrier

Asked what slows translation from lab to clinic and manufacturing, Dr. Alshaya names fragmentation. “Translation stalls when discovery, regulation, manufacturing, capital, and clinical delivery run on separate timelines,” he says.

In 2023, the Saudi Food and Drug Authority (SFDA) reached Maturity Level 4, the highest level of the World Health Organization’s Global Benchmarking Tool, becoming the first regulator in WHO’s Eastern Mediterranean Region and the third worldwide to do so. The remaining task, he says, is connecting regulation, integrated R&D clusters, manufacturing, and capital into one predictable path, with returns coming from steady execution toward 2040.

What organizers plan next

The team’s main lesson is that the Kingdom’s value lies in activating existing capabilities in clinical infrastructure, genomic data, research institutions, and manufacturing, rather than building new ones. This is the practical route to the National Biotechnology Strategy’s 2040 goals. The next edition will structure matchmaking around specific projects instead of corridor introductions, and organizers plan to report publicly on all 46 agreements. “Visible follow-through is what sustains investor confidence,” Dr. Alshaya says.

“Come seeking co-development, not only capital deployment,” Dr. Alshaya tells international partners. Start with one defined project rather than a broad memorandum. Settle data, intellectual property, and publication terms early. Engage the regulator before the study design is fixed. KAIMRC, he adds, can host a first collaboration.